Immunovant (IMVT) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Key accomplishments and 2024 progress

• Achieved five IND clearances, with two pivotal trials (Graves' and RA) now enrolling in the US using a commercial-ready auto-injector.

• Completed enrollment for MG trials, with data expected this quarter.

• Announced a PIPE financing that significantly strengthened the balance sheet, with $473M in cash and a $450M PIPE in January 2025.

• Secured a strong composition of matter patent to 2043, covering method of use and manufacturing.

• Built an experienced leadership team and robust intellectual property portfolio, supporting execution of ambitious clinical and commercial plans.

Clinical data and market opportunity

• Batoclimab and IMVT-1402 have shown dose-dependent, deep IgG reduction and strong clinical efficacy in Graves' disease, with high response and ATD-free rates.

• High-dose batoclimab achieved a 77% IgG reduction and a 56% ATD responder rate, outperforming standard doses.

• In Graves' disease, 25-30% of patients are relapsed, uncontrolled, or intolerant to ATDs, representing about 330K prevalent US patients and a significant commercial opportunity.

• Market research indicates about one-third of Graves' patients have unmet needs, with growing physician enthusiasm for new therapies.

• Myasthenia gravis and CIDP represent additional large markets, with tailored dosing and subcutaneous administration addressing unmet needs.

Auto-injector and development speed

• Achieved rapid transition to a commercial auto-injector, using the YpsoMate platform, within 1.5 years of first-in-human dosing.

• Benchmarking shows industry median is 7.5 years for similar transitions.

• All pivotal trials are using the commercial auto-injector, eliminating the need for bridging studies.

• IMVT-1402 is delivered via a user-friendly autoinjector; pivotal trials are enrolling in multiple indications.